Table 1.
Fbg levels and clinical characteristics of 120 patients with SCLC analyzed using the Kaplan–Meier method (log‐rank test)
| Variable | No. of patients (%) | MST (months) | P |
|---|---|---|---|
| Gender | 0.871 | ||
| Male | 86 (71.7%) | 12 | |
| Female | 34 (28.3%) | 14 | |
| Age (year) | 0.003 | ||
| < 65 | 61 (50.8%) 54.8 ± 7.2 |
15 | |
| ≥ 65 | 59 (49.2%) 72.0 ± 5.2 |
8 | |
| Smoking status | 0.325 | ||
| Never | 33 (27.5%) | 15 | |
| Ever | 87 (72.5%) | 12 | |
| Alcohol use | 0.018 | ||
| Never | 88 (73.3%) | 10 | |
| Ever | 32 (26.7%) | 18 | |
| Clinical stage | < 0.001 | ||
| LD | 47 (39.2%) | 19 | |
| ED | 73 (60.8%) | 10 | |
| Pleural effusion | 0.002 | ||
| No | 70 (58.3%) | 15 | |
| Yes | 50 (41.7%) | 9 | |
| Vascular invasion | 0.803 | ||
| No | 92 (76.7%) | 12 | |
| Yes | 28 (23.3%) | 14 | |
| Brain metastases | 0.112 | ||
| No | 110 (91.7%) | 13 | |
| Yes | 10 (8.3%) | 10 | |
| ECOG grade | < 0.001 | ||
| 0–2 | 92 (76.7%) | 14 | |
| 3–4 | 28 (23.3%) | 8 | |
| Fbg (mg/dL) | 0.013 | ||
| ≤ 400 | 65 (54.2%) | 15 | |
| > 400 | 55 (45.833%) | 8 | |
| LDH (U/L) | 0.001 | ||
| 80–250 | 56 (46.7%) | 18 | |
| > 250 | 64 (53.3%) | 8 | |
| Albumin (g/L) | 0.058 | ||
| 40–55 | 58 (48.3%) | 11 | |
| < 40 | 62 (51.7%) | 13 |
ECOG, Eastern Cooperative Oncology Group; ED, extensive disease; Fbg, fibrinogen; LD, limited disease; LDH, lactate dehydrogenase; MST, median survival time; SCLC, small‐cell lung carcinoma.